Premium
Update of ELITE‐II, BEST, CHAMP, and IMPRESS clinical trials in heart failure
Author(s) -
Witte Klaus,
Thackray Simon,
Banerjee Tumpa,
Clark Andrew L.,
Cleland John G.F.
Publication year - 2000
Publication title -
european journal of heart failure
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.149
H-Index - 133
eISSN - 1879-0844
pISSN - 1388-9842
DOI - 10.1016/s1388-9842(00)00053-2
Subject(s) - medicine , heart failure , clinical trial , myocardial infarction , clinical practice , intensive care medicine , mandate , management of heart failure , cardiology , physical therapy , political science , law
The ELITE‐II, BEST and CHAMP Trials were reported for the first time at the American Heart Association in November 1999. These trials provide valuable new information to guide clinical practice in the management of heart failure and of myocardial infarction, although none mandate a major change from current clinical practice. The IMPRESS trial of the vasopeptidase inhibitor, omapatrilat, indicated a promising new treatment for the management of heart failure.